Africa: Lifesaving TB Medicines Still Out of Reach for Children in High-Burden Countries
[MSF] The World Health Organization (WHO) recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - September 3, 2021 Category: Infectious Diseases Source Type: news

Government slashes prices of about 39 commonly-used drugs
The drugs brought under price control include teneligliptin-an anti diabetes drug, popular anti TB drugs like Bedaquiline and Delamanid, Ivermectin used in Covid treatment, Rotavirus vaccine, among others. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 3, 2021 Category: Pharmaceuticals Source Type: news

BPaL regimen can cut time for treatment of drug-resistant TB
BPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB Alliance developed antibiotic pretomanid, along with two other antibiotics: bedaquiline and linezolid. (Source: The Economic Times)
Source: The Economic Times - July 22, 2021 Category: Consumer Health News Source Type: news

Africa: Active TB Drug Safety Monitoring and Management (ADSM) Global Database - Outcome of the Assessment and Future of Data Reporting
[WHO] A global database set up by WHO's Global Tuberculosis Programme in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR) has been collating data on Active TB Drug Safety Monitoring and Management (aDSM) since 2016, to monitor the safety of patients who receive MDR-TB treatment with new medicines (e.g. bedaquiline, delamanid), repurposed medicines (e.g. linezolid, clofazimine) or new regimens, which don't have a well-established safety profile. The aDSM framework has (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - July 12, 2021 Category: Infectious Diseases Source Type: news

Bedaquiline for Disseminated NTM Infection in HIV Patients Bedaquiline for Disseminated NTM Infection in HIV Patients
Could this novel antimycobacterial agent provide a safe and effective treatment option for NTM infections in HIV patients?Emerging Infectious Diseases (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 6, 2021 Category: Infectious Diseases Tags: Infectious Diseases Journal Article Source Type: news

Trinity scientists find that binding iron improves the effect of anti-TB drug Bedaquiline
(Trinity College Dublin) For some time, scientists have known that depriving infections of iron can limit bacterial burden and help improve patient outcomes. Now scientists at Trinity College and St James's Hospital have recently applied such a trick (of binding iron to support the immune system) to the treatment of TB, along with a new TB antimicrobial called Bedaquiline. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 22, 2021 Category: Infectious Diseases Source Type: news

Bedaquiline and Delamanid Safe Together Against Rifampicin-Resistant TB Bedaquiline and Delamanid Safe Together Against Rifampicin-Resistant TB
New research suggests concerns over the concurrent use of bedaquiline and delamanid in patients with drug-resistant tuberculosis were unwarranted.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 1, 2021 Category: Infectious Diseases Tags: Pulmonary Medicine News Source Type: news

South Africa: Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
[TB Alliance] TB Alliance welcomes the Wits Health Consortium and the South African National Department of Health (DoH)'s announcement of an initiative to provide a new, shorter treatment regimen for people affected with highly drug-resistant forms of tuberculosis (TB). Funded by the United States Agency for International Development, a new clinical access program (CAP) will enroll 400 people in South Africa for treatment with a three-drug, six-month, all-oral regimen of bedaquiline, pretomanid and linezolid (know (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 10, 2020 Category: African Health Source Type: news

New generation of drugs show early efficacy against drug-resistant TB
(Harvard Medical School) New drug regimen for multidrug-resistant tuberculosis shows early effectiveness in 85 percent of patients in a cohort including many with serious comorbidities. The results suggest a global need for expanded access to two recently developed medicines, bedaquiline and delamanid. Study cohort included many people who would have been excluded from trials because of comorbidities, severity of disease or extent of drug resistance. Findings highlight the importance of innovative regimens to improve outcomes for patients with multidrug-resistant tuberculosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Africa: MSF Welcomes Price Cut On Lifesaving TB Drug
[MSF] New York/Geneva -- The international medical humanitarian organization Doctors Without Borders/M édecins Sans Frontières (MSF) welcomes Johnson& Johnson's (J&J) announcement today to reduce the price of its tuberculosis (TB) drug bedaquiline to $1.50 per day. Governments must now urgently scale up the use of the treatment as a core part of drug-resistant TB (DR-TB) regimens, MSF said. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 7, 2020 Category: African Health Source Type: news

Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO ® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
GENEVA, SWITZERLAND, 6 JULY 2020 – The Stop TB Partnership and Johnson & Johnson – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO® (bedaquiline) 100mg tablets in support of new, recently-released World Health Organization (WHO) treatment guidelines. Effective immediately, Johnson & Johnson will make bedaquiline available to Stop TB Partnership’s Global Drug Facility (GDF) at a price of USD$340 per six-month treatment c...
Source: Johnson and Johnson - July 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves New Pediatric Formulation of Sirturo (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
NEW BRUNSWICK, NJ, May 27, 2020— The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of Sirturo (bedaquiline).... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 27, 2020 Category: Drugs & Pharmacology Source Type: news

U.S. FDA Approves New Pediatric Formulation of SIRTURO ® (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelerated appro...
Source: Johnson and Johnson - May 27, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

EMA Panel Backs Pretomanid for Drug-Resistant TB EMA Panel Backs Pretomanid for Drug-Resistant TB
Pretomanid FGK, in combination with bedaquiline and linezolid, is for adults with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant tuberculosis.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 31, 2020 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news